^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification

Excerpt:
This report presents a patient with metastatic HR+ HER2- breast cancer harboring an FGFR1 amplification who was resistant to endocrine therapy but responded to pazopanib, a multi-tyrosine kinase inhibitor with FGFR-inhibiting activity.
DOI:
10.6004/jnccn.2017.7030